Paper283266
Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose.
Stutman O. J Natl Cancer Inst, 1979. Cited by 95 papers, by iCite.
Cite this record
ConductScience Library. Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. Papers, record 283266. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/283266
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Methylcholanthrene | Major topic |
| Mice, Nude | Major topic |
| Sarcoma, Experimental | Major topic |
| Age Factors | |
| Animals | |
| Dose-Response Relationship, Drug | |
| Female | |
| Heterozygote | |
| Homozygote | |
| Immunosuppression Therapy | |
| Male | |
| Mice | |
| Mice, Inbred CBA | |
| Pregnancy | |
| Time Factors |
Source PubMed
Cited by37
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 95 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42649983 | 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42649983 | PubMed |
| 38042584 | Recent advances in immunopeptidomic-based tumor neoantigen discovery. | Adv Immunol | 2023 | https://conductscience.org/library/papers/38042584 | PubMed |
| 36672607 | Association between Immunosuppressive Therapy Utilized in the Treatment of Autoimmune Disease or Transplant and Cancer Progression. | Biomedicines | 2022 | https://conductscience.org/library/papers/36672607 | PubMed |
| 34697663 | Malignancy: An Adverse Effect of Immunosuppression. | Handb Exp Pharmacol | 2022 | https://conductscience.org/library/papers/34697663 | PubMed |
| 31921205 | The Intriguing History of Cancer Immunotherapy. | Front Immunol | 2019 | https://conductscience.org/library/papers/31921205 | PubMed |
| 31831634 | Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors. | Cancer Immunol Res | 2020 | https://conductscience.org/library/papers/31831634 | PubMed |
| 31557983 | Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? | Antibodies (Basel) | 2015 | https://conductscience.org/library/papers/31557983 | PubMed |
| 31216652 | Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31216652 | PubMed |
| 29900059 | The possibility of cancer immune editing in gliomas. A critical review. | Oncoimmunology | 2018 | https://conductscience.org/library/papers/29900059 | PubMed |
| 29311379 | A Believer's Overview of Cancer Immunosurveillance and Immunotherapy. | J Immunol | 2018 | https://conductscience.org/library/papers/29311379 | PubMed |
| 28609371 | Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Human Disease. | Pancreas | 2017 | https://conductscience.org/library/papers/28609371 | PubMed |
| 28534024 | Cancer Immunoprevention and Public Health. | Front Public Health | 2017 | https://conductscience.org/library/papers/28534024 | PubMed |
| 26922999 | The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. | Adv Immunol | 2016 | https://conductscience.org/library/papers/26922999 | PubMed |
| 26464579 | Curcumin and tumor immune-editing: resurrecting the immune system. | Cell Div | 2015 | https://conductscience.org/library/papers/26464579 | PubMed |
| 26435343 | Tolerance and immune suppression in the tumor microenvironment. | Cell Immunol | 2016 | https://conductscience.org/library/papers/26435343 | PubMed |
| 24860566 | Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy. | Front Immunol | 2014 | https://conductscience.org/library/papers/24860566 | PubMed |
| 24657536 | The importance of animal models in tumor immunity and immunotherapy. | Curr Opin Genet Dev | 2014 | https://conductscience.org/library/papers/24657536 | PubMed |
| 24324471 | Tumor-primed NK cells: waiting for the green light. | Front Immunol | 2013 | https://conductscience.org/library/papers/24324471 | PubMed |
| 24133490 | How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development. | Front Immunol | 2013 | https://conductscience.org/library/papers/24133490 | PubMed |
| 22936035 | Improving T cell responses to modified peptides in tumor vaccines. | Immunol Res | 2013 | https://conductscience.org/library/papers/22936035 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/283266
GET https://conductscience.org/api/papers/v1/283266/cited_by?page=2